aTyr Pharma Inc.

228 articles with aTyr Pharma Inc.

• Leading Cancer Researcher Dr. Arthur M. Mercurio Joins aTyr as Scientific AdvisorDr. Mercurio to advise company on the development of novel antibody therapeutics targeting neuropilin-2 (NRP2) for cancer

  3/17/2020

  aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, announced the appointment of Arthur M. Mercurio, Ph.D. as a scientific advisor to the company.

• aTyr Pharma Announces Exercise and Closing of Over-Allotment Option in Public Offering

  3/10/2020

  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced the underwriters of its previously announced public offering of common stock have fully exercised their over-allotment option resulting in the issuance of an additional 635,294 shares of common stock. The option was granted in connection with the public offering of 4,235,

• aTyr Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting

  3/3/2020

  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the company will present an abstract in a poster session at the upcoming AACR Annual Meeting, which is being held April 24 – 29, 2020 at the San Diego Convention Center.

• aTyr Pharma Announces Publication in the Journal Cellular and Molecular Immunology

  2/27/2020

  Paper highlights the essential role thathistidyl tRNA synthetase (HARS) plays in immune responses in a broad range of inflammatory disease states

• aTyr Pharma Announces Pricing of $18 million Underwritten Public Offering

  2/6/2020

  SAN DIEGO, Feb. 06, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced the pricing of an underwritten public offering of 4,235,294 shares of its common stock at a price to the public of $4.25 per share. The offering is expected to close on or about February 10, 2020, subject to customary closing conditions. aTyr has also granted the underwrit

• 

  Clinical Catch-Up: December 9-13

  12/16/2019

  It was a particularly busy week in clinical trial news, largely because of the American Society of Hematology Annual Meeting. Here’s a look.

• aTyr Pharma Announces Positive Interim Safety Results from Ongoing Phase 1b/2a Clinical Trial of ATYR1923

  12/12/2019

  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced the results of a pre-planned, blinded interim analysis of safety and tolerability, the primary endpoint of its ongoing Phase 1b/2a clinical trial of its lead therapeutic candidate, ATYR1923, in patients with pulmonary sarcoidosis.

• aTyr Pharma Announces Third Quarter 2019 Results and Provides Corporate Update

  11/14/2019

  Interim safety results from Phase 1b/2a proof-of-concept trial of ATYR1923 in pulmonary sarcoidosis patients due in December 2019

• aTyr Pharma to Present at the Stifel Healthcare Conference 2019

  11/13/2019

  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Dr. Sanjay Shukla, President and Chief Executive Officer of aTyr, will be presenting at the Stifel Healthcare Conference 2019, which is being held November 19-20 in New York.

• aTyr Pharma to Announce Third Quarter Results on November 14thManagement to host conference call and webcast at 5:00 pm EST / 2:00 pm PST

  11/7/2019

  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report third quarter 2019 results after the market close on Thursday, November 14, 2019.

• aTyr Pharma Announces Research Collaboration with Boston Children’s HospitalCollaboration to examine the therapeutic efficacy of anti-neuropilin-2 (NRP2) antibodies in potential new roles and indications

  10/22/2019

  Dr. Diane Bielenberg, Assistant Professor in the Department of Surgery at Harvard Medical School and a Research Associate in the Vascular Biology Program at Boston Children’s, will serve as the principal investigator for the collaboration.

• aTyr Pharma Announces Positive Phase 1 Data for ATYR1923 Therapeutic Candidate

  6/26/2018

  aTyr Pharma Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced positive data from its Phase 1 clinical trial of ATYR1923, an immuno-modulatory therapeutic candidate with potentially broad therapeutic application in the treatment of interstitial lung diseases.

• 

  aTyr Pharma Slashes 30% of Employees as it Initiates Corporate Restructuring Following ORCA Failure

  5/14/2018

  Shares of San Diego-based aTyr Pharma are down nearly 20 percent this morning after the company announced a corporate restructuring plan that includes a 30 percent reduction of staff following failures of its preclinical ORCA program.

• aTyr Pharma Doses First Subjects in Phase I Trial of iMod.Fc (ATYR1923)

  11/27/2017

  This first-in-human, randomized, double-blind, placebo-controlled study is designed to investigate the safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics of intravenous iMod.Fc in healthy volunteers.

• aTyr Pharma Announces Third Quarter 2017 Operating Results and Provides Corporate Update

  11/15/2017

  Research and development expenses were $7.1 million and $10.4 million for the three months ended September 30, 2017 and 2016, respectively. T

• 

  aTyr Promotes CMO to CEO

  11/2/2017

  aTyr Pharma announced that today Sanjay Shukla, M.D., M.S., who joined aTyr Pharma as CMO in March 2016, will succeed John Mendlein, Ph.D., as President and CEO.

• aTyr Pharma To Present Final Data For Resolaris Phase Ib/II Trial In Patients With Early-Onset Facioscapulohumeral Muscular Dystrophy At The 22nd International Annual Congress Of The World Muscle Society

  9/27/2017

• aTyr Pharma, A US-Hong Kong Biotech, Announces $46 Million Private Placement

  8/29/2017

• San Diego's aTyr Pharma Nabs $45 Million Equity Financing

  8/28/2017

• aTyr Pharma Announces Second Quarter 2017 Operating Results And Provides An Update On Innovative Immunology Pipeline

  8/15/2017